I'm wondering about the negatives to this report. NTA has fallen considerably. Cost of revenue almost doubled without the doubling of revenue. Most increases in staff and R&D. What else is there to R&D?
ARR looks really good. Currently trading on 15 times price/ earnings but cash has fallen near 30%.